Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21:501–21.
Xia T, Konno H, Barber GN. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 2016;76:6747–59.
Garland KM, Sheehy TL, Wilson JT. Lindsay KE. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem Rev. 2022;122:5977–6039.
Wang B, Yu W, Jiang H, Meng X, Tang D, Liu D. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects. Front Immunol. 2024;15:1485546.
Chen S, Peng A, Chen M, Zhan M. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy. Front Oncol. 2023;12:1093240.
Najem H, Lea ST, Tripathi S, Hurley L, Chen CH, William I, et al. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J Clin Invest. 2024;134:e175033.
Li T, Zhang W, Niu M, Wu Y, Deng X, Zhou J. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance. Front Immunol. 2024;15:1342647.
Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science. 2015;350:568–71.
Wu JJ, Li W, Shao Y, Avey D, Fu B, Gillen J, et al. Inhibition of cGAS DNA sensing by a herpesvirus virion protein. Cell Host Microbe. 2015;18:333–44.
Lou M, Huang D, Zhou Z, Shi X, Wu M, Rui Y, et al. DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation. J Med Virol. 2023;95:e28310.
Burke MJ. Oncolytic Seneca Valley virus: past perspectives and future directions. Oncolytic Virother. 2016;5:81–9.
Zhao X, Li W, Sun Y, Ma J. Oncolytic senecavirus A in tumor immunotherapy: mechanisms, progress, and future directions. Virology. 2025;603:110338.
Reddy PS, Burroughs KD, Hales LM, Ganly I, Jones BH, Idamakanti N, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99:1623–33.
Li H, Wang X, Chen Y, Zhao Z, Liu S, Zhou J. Senecavirus A-induced glycolysis facilitates virus replication by promoting lactate production that attenuates the interaction between MAVS and RIG-I. PLoS Pathog. 2023;19:e1011371.
Xue J, Liu Y, Zhang Q, Chen H, Li L, Gao P, et al. Seneca Valley virus 3Cpro antagonizes host innate immune responses. Front Immunol. 2020;11:567853.
Wen W, Li X, Wang H, Zhao Q, Yin M, Liu W, et al. Seneca Valley virus 3C protease induces pyroptosis by directly cleaving porcine gasdermin D. J Immunol. 2021;207:189–99.
Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, et al. Phase I clinical study of Seneca Valley virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17:888–95.
Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, et al. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive-stage SCLC who were stable or responding after at least four cycles of platinum-based chemotherapy. J Thorac Oncol. 2020;15:110–9.
Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small-cell lung cancer. J Natl Cancer Inst. 2013;105:1059–65.
Bryant JD, Lee JS, De Almeida A, Jacques J, Chang CH, Fassler W, et al. Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression. Mol Ther Oncolytics. 2023;28:321–33.
Tur-Planells V, García-Sastre A, Cuadrado-Castano S, Nistal-Villan E. Engineering non-human RNA viruses for cancer therapy. Vaccines. 2023;11:1617.
Pantelidou C, Sonzogni O, De Oliveira Taveira T, Mezzadra R, Seo H, Gaines T, et al. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. NPJ Breast Cancer. 2022;8:102.
Trottier MD Jr, Palian BM, Reiss CS. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection. Virology. 2005;333:215–25.
Danastas K, Miranda-Saksena M, Cunningham AL. Herpes simplex virus type 1 interactions with the interferon system. Int J Mol Sci. 2020;21:5150.
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.
Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20:1574–83.
Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol. 2019;4:914–24.
Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6:644–58.
Chen Y, Zhong W, Xie Z, Li B, Li H, Gao K, et al. Suppressor of cytokine signaling 1 (SOCS1) inhibits antiviral responses to facilitate Senecavirus A infection by regulating the NF-κB signaling pathway. Virus Res. 2022;313:198748.
Zhang Z, Zhou H, Ouyang X, Dong Y, Sarapultsev A, Luo S, et al. Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy. Signal Transduct Target Ther. 2022;7:394.
Hu PY, Fan XM, Zhang YN, Huang QY, Dong XQ, Chen Y. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol. 2020;104:8231–42.
Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8:156.
Czapla J, Drzyzga A, Matuszczak S, Cichoń T, Rusin M, Jarosz-Biej M, et al. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context. Front Oncol. 2023;13:1249524.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10–21.
Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81.
Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507–19.
Heintzman DR, Fisher EL, Rathmell JC. Microenvironmental influences on T cell immunity in cancer and inflammation. Cell Mol Immunol. 2022;19:316–26.
Heras-Murillo I, Muntasell A, Aguiló N, Romero P, Coukos G, Galluzzi L, et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257–77.
Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19:120.
Philip M, Schietinger A. CD8⁺ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209–23.
Yang I, Tihan T, Han SJ, Chang SM, Parsa AT, Berger MS. CD8⁺ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010;17:1381–5.
Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8⁺ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359–67.
Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8⁺ T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75:689–713.
Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, et al. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. J Exp Med. 2022;219:e20212169.
